ST. ALBANS, Mo. – Tournament scoring records are falling – or at least being matched – every day at the Country Club of St. Albans, (...)
NYS Entity Status
NYS Filing Date
OCTOBER 29, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - LINDEN CONVENIENCE CORP.
AROUND THE WEB
- Rose Zhang opens sizable 54-hole lead amidst stunning low scores at Girls Junior PGA
By Kevin Casey - Friday Jul 21, 2017
- Hailee Cooper overcomes triple bogey to retain lead at Girls Junior PGA
By Kevin Casey - Wednesday Jul 19, 2017
Leaderboard • • • ST. ALBANS, Mo. – It could have fallen apart on Hailee Cooper’s back nine. The 17-year-old had been (...)
- Marine Corps Plane Crash: The Victims
By THE NEW YORK TIMES - Thursday Jul 13, 2017
Family members and friends have begun identifying many of the 16 American service members who died on Monday when their plane crashed in rural Mississippi.
- Could the Rockaways Survive Another Sandy?
By LUIS FERRÉ-SADURNÍ - Thursday Jul 13, 2017
Residents are bracing for the worst, wondering whether measures taken so far are enough to keep devastation of the Queens community at bay.
- FDA advisers review data on potential 1st US gene therapy
By LINDA A. JOHNSON, AP Medical Writer - Wednesday Jul 12, 2017
Cancer experts who advise government regulators are reviewing what could be the first gene therapy approved in the U.S.The Food and Drug Administration panel is holding a hearing Wednesday to discuss the treatment developed by the University of Pennsylvania and Novartis Corp. The drugmaker is seeking approval to use the one-time treatment for children and young adults with advanced leukemia.
- Novel leukemia treatment could be 1st US gene therapy
By Associated Press - Thursday Jul 13, 2017
A treatment for a common childhood blood cancer could become the first gene therapy available in the U.S. A Food and Drug Administration advisory panel voted 10-0 on Wednesday in favor of the leukemia treatment developed by the University of Pennsylvania and Novartis Corp. The FDA usually follows recommendations from its expert panels, but isn’t...